Teva Pharmaceuticals USA Inc 2022-04-20 Health critical FDA
Health · FDA · Recall #FDA-D-0765-2022
IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single… Recall
Issued April 20, 2022 · Teva Pharmaceuticals USA Inc
In April 2022, Teva Pharmaceuticals USA Inc recalled the IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single…, a critical health recall reported by the FDA. Affected owners are eligible for a voluntary. Here is what the hazard is and exactly what to do about it.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Presence of Particulate Matter: Product was found to contain silica and iron oxide
What you should do
- 1 Stop using IDArubicin Hydrochloride Injection USP 5gm/5mL (1mg/mL) for intravenous use, 5mL Single… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Teva Pharmaceuticals USA Inc to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Teva Pharmaceuticals USA Inc
- Category
- Health
- Recall date
- April 20, 2022
- Units affected
- Not reported
- Sold at
- Nationwide within the United States
- Recall number
- FDA-D-0765-2022
- Made in
- United States
- Issuing agency
- FDA
In context
- Teva Pharmaceuticals USA Inc has 8 recalls in our database, including 1 rated Critical.
- We're tracking 3,576 Health recalls in our database.
- This is the 870th Health recall we've logged in 2022.